Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.9946
+0.0113 (1.15%)
May 7, 2026, 10:02 AM EDT - Market open
Humacyte Employees
Humacyte had 184 employees as of December 31, 2025. The number of employees decreased by 36 or -16.36% compared to the previous year.
Employees
184
Change (1Y)
-36
Growth (1Y)
-16.36%
Revenue / Employee
$11,076
Profits / Employee
-$221,918
Market Cap
220.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 184 | -36 | -16.36% | 184 | 0 |
| Dec 31, 2024 | 220 | 35 | 18.92% | 218 | 2 |
| Dec 31, 2023 | 185 | 21 | 12.80% | 183 | 2 |
| Dec 31, 2022 | 164 | 18 | 12.33% | 164 | 0 |
| Dec 31, 2021 | 146 | - | - | 145 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Tonix Pharmaceuticals Holding | 142 |
| MediWound | 121 |
| Nkarta | 108 |
| OmniAb | 89 |
| Keros Therapeutics | 78 |
| Camp4 Therapeutics | 48 |
| Sol-Gel Technologies | 28 |
HUMA News
- 9 days ago - Humacyte Transcript: KOL event - Transcripts
- 10 days ago - Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - GlobeNewsWire
- 12 days ago - Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA - PRNewsWire
- 13 days ago - Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® - GlobeNewsWire
- 15 days ago - Humacyte Appoints Jim Mercadante as Chief Commercial Officer - GlobeNewsWire
- 16 days ago - Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair - GlobeNewsWire
- 27 days ago - Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 5 weeks ago - Humacyte Earnings Call Transcript: Q4 2025 - Transcripts